Literature DB >> 23506207

Biopharmaceutical formulations for pre-filled delivery devices.

Jan Jezek1, Nicholas J Darton, Barry K Derham, Nikki Royle, Iain Simpson.   

Abstract

INTRODUCTION: Pre-filled syringes are becoming an increasingly popular format for delivering biotherapeutics conveniently and cost effectively. The device design and stable liquid formulations required to enable this pre-filled syringe format are technically challenging. In choosing the materials and process conditions to fabricate the syringe unit, their compatibility with the biotherapeutic needs to be carefully assessed. The biothereaputic stability demanded for the production of syringe-compatible low-viscosity liquid solutions requires critical excipient choices to be made. AREAS COVERED: The purpose of this review is to discuss key issues related to the stability aspects of biotherapeutics in pre-filled devices. This includes effects on both physical and chemical stability due to a number of stress conditions the product is subjected to, as well as interactions with the packaging system. Particular attention is paid to the control of stability by formulation. EXPERT OPINION: We anticipate that there will be a significant move towards polymer primary packaging for most drugs in the longer term. The timescales for this will depend on a number of factors and hence will be hard to predict. Formulation will play a critical role in developing successful products in the pre-filled syringe format, particularly with the trend towards concentrated biotherapeutics. Development of novel, smart formulation technologies will, therefore, be increasingly important.

Mesh:

Substances:

Year:  2013        PMID: 23506207     DOI: 10.1517/17425247.2013.780023

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  4 in total

1.  Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.

Authors:  Lea L Sorret; Madison A DeWinter; Daniel K Schwartz; Theodore W Randolph
Journal:  Protein Sci       Date:  2018-03-03       Impact factor: 6.725

2.  In Vivo Analysis of the Potency of Silicone Oil Microdroplets as Immunological Adjuvants in Protein Formulations.

Authors:  Carly Fleagle Chisholm; Bao Han Nguyen; Kaitlin R Soucie; Raul M Torres; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-07-17       Impact factor: 3.534

3.  Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice.

Authors:  Carly Fleagle Chisholm; Abby E Baker; Kaitlin R Soucie; Raul M Torres; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2016-03-25       Impact factor: 3.534

Review 4.  Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.

Authors:  Zhaoyang Li; Rachael Easton
Journal:  MAbs       Date:  2017-11-07       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.